Profil bibliographique

Anne-Liv Schulz

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

6Publications signalées

2Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

Epilepsy research and treatmentPharmacological Effects and Toxicity StudiesSchizophrenia research and treatmentAttention Deficit Hyperactivity DisorderNeurological disorders and treatments

Les publications récentes

2024 article OpenAlex

Brivaracetam Adjunctive Therapy in Earlier Treatment Lines in Adults with Focal-onset Seizures in Europe and Canada: Interim Results of 12-month Real-world Data From BRITOBA (P8-1.008)

Susanne Knake, Marco de Curtis, Elaine Kobayashi, Teresa Lema-Facal et autres

Evaluate effectiveness of adjunctive brivaracetam (BRV) in earlier treatment lines in adults with focal-onset seizures (FOS) for ≤12months(m).

au, it, ca, es, fr, be (code pays fourni par la source)

2 citations Neurology

2023 article OpenAlex

Effectiveness and Tolerability of Brivaracetam by Number of Lifetime Antiseizure Medications in Adults with Focal Onset Seizures: Pooled Data From Two Real-world Studies (P11-1.010)

Melinda S. Martin, Dimitrios Bourikas, F Brock, Prashant Dongre et autres

Objective: Analyze impact of number of lifetime antiseizure medications (ASMs) on effectiveness and tolerability of brivaracetam (BRV) in adults with focal-onset seizures in a real-world clinical setting. Background: Increasing number of lifetime ASMs is associated with poorer response to newly administered ASM. …

be (code pays fourni par la source)

0 citations Neurology

2023 article OpenAlex

Treatment Outcomes During Brivaracetam Treatment by Seizure Freedom Status at Baseline: Post hoc Analysis of a Real-world, US Study (P14-1.001)

Hina Dave, Jacqueline A. French, Heidi Henninger, Hamada Altalib et autres

Objective: Examine the relationship between baseline seizure control as well as clinical characteristics and outcomes on brivaracetam (BRV). Background: EP0088 (Dave H, et al. AES 2021; abstract 2.203) assessed clinical utility of BRV by examining 6- and 12-month retention after BRV initiation …

us, au, be (code pays fourni par la source)

0 citations Neurology

2022 article OpenAlex

Patient-reported Outcomes in Mood, Fatigue, Sleep Disturbance, and Disability While on Brivaracetam Treatment: a Prospective Observational Study (P17-8.002)

Hamada Altalib, Jacqueline A. French, Michael R. Sperling, Heidi Henninger et autres

Measure patient perception of change in mood/fatigue/sleep disturbance/disability during brivaracetam (BRV) treatment using patient-reported outcomes (PROs): validated PRO Measurement Information System (PROMIS), new Seizure-Related Disability Assessment Scale (SERDAS).

us, au, be (code pays fourni par la source)

0 citations Neurology

2022 article OpenAlex

Real-world Study of Brivaracetam in the United States (S13.001)

Hina Dave, Jacqueline A. French, Hamada Altalib, Heidi Henninger et autres

To assess effectiveness of adjunctive brivaracetam (BRV) in adults with focal seizures as measured by retention.

us, au, be (code pays fourni par la source)

0 citations Neurology

2022 article OpenAlex

Effectiveness and Tolerability of Brivaracetam by Reason for Initiation in Adults with Focal Seizures: Post-hoc Analysis of a Real-world, US Study (P15-8.003)

Heidi Henninger, Michael R. Sperling, Hamada Altalib, Hina Dave et autres

Assess long-term real-world effectiveness and tolerability of brivaracetam (BRV) in adults with focal seizures by reason for BRV initiation.

us, be, au (code pays fourni par la source)

0 citations Neurology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.